Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431146 | 0.92 | POLB (0.39) | CTSAKMT2APOLBSMN1; SMN2FPR1 | |
| SCHEMBL4437344 | 0.90 | SMN1; SMN2 (0.48) | KMT2APOLBSMN1; SMN2FPR1FPR2 | |
| SCHEMBL4429736 | 0.89 | CTSA (0.41) | CTSAKMT2APOLBSMN1; SMN2FPR1 | |
| SCHEMBL7433099 | 0.89 | FPR1 (0.39) | CTSAKMT2APOLBSMN1; SMN2FPR1 | |
| SCHEMBL4430605 | 0.88 | CTSA (0.39) | CTSAKMT2AFPR1 | |
| SCHEMBL8517291 | 0.88 | CTSA (0.39) | CTSAKMT2AFPR1 | |
| SCHEMBL4430603 | 0.88 | CTSA (0.39) | CTSAKMT2AFPR1 | |
| SCHEMBL4424311 | 0.87 | CTSA (0.39) | CTSAPOLBSMN1; SMN2FPR1FPR2 | |
| SCHEMBL8506622 | 0.87 | CTSA (0.40) | CTSAFPR1 | |
| SCHEMBL4435400 | 0.87 | CTSA (0.40) | CTSAFPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | claimed |
| EP-1213288-B1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | CTSA 1318/4885KMT2A 4655/4885POLB 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.